Clinical trials: Overweight or Obesity, open to volunteers
Obesity, Overweight
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07654972
- Testing
- LY4174794
- Where
- 3 sites in United States, Singapore
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Weight Maintenance
Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging.
- Trial name
- AFTER-GLP (NCT07701460)
- Testing
- Digital Behavioral Application
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Tufts University
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Obesity
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the…
- Trial name
- NCT07794761
- Testing
- Berobenatide
- Where
- 34 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Pfizer
Overweight and Obesity in Adults Receiving GLP-1RA Treatment
Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss
The goal of this clinical trial is to evaluate whether yeast protein supplementation can help preserve lean body mass and muscle function in adults with overweight or obesity receiving GLP-1 receptor agonist-related treatment for…
- Trial name
- NCT07817823
- Testing
- Yeast Protein, Whey Protein, Yeast Protein/Whey Protein Blend (1:1)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Huazhong University of Science and Technology
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Obesity, Overweight and/or Obesity
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
- Trial name
- NCT07845500
- Testing
- Semaglutide, Berobenatide, Tirzepatide
- Where
- 16 sites in United States
- Volunteers
- 660 people
- Sponsor
- Pfizer
Obesity / Overweight
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
This is an observational cohort study. The primary objective is to analyze the dynamic changes in gut microbiota and metabolic profiles in obese patients treated with Tirzepatide.
- Trial name
- NCT07847515
- Testing
- Tirzepatide
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 2 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus)
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function
This is an open-label, non-randomized study to assess how DA-302168S is absorbed, distributed, metabolized, and eliminated after a single oral dose.
- Trial name
- NCT07877038
- Testing
- DA-302168S
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Overweight , Obesity
Study of UBT37034 Injection
This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated…
- Trial name
- NCT07873645
- Testing
- UBT37034
- Volunteers
- 40 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Obesity or Overweight, Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith2 (NCT07351058)
- Testing
- Enicepatide
- Where
- 210 sites in United States, Argentina and 19 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Trial name
- NCT07595549
- Testing
- PF-08653944
- Where
- 72 sites in United States, Brazil and 9 more
- Volunteers
- 954 people
- Sponsor
- Pfizer
Obesity, Overweight
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose…
- Trial name
- NCT07628127
- Testing
- VRB-103, VRB-101
- Where
- 3 sites in Australia
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Verdiva Bio Dev Limited
Obesity & Overweight, Coronary Heart Disease
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography…
- Trial name
- NCT07657676
- Testing
- Mazdutide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- China National Center for Cardiovascular Diseases
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals